Micronized progesterone and its impact on the endometrium and breast vs. progestogens

Climacteric

Volumn 15, Issue SUPPL.1, 2012, Pages 18-25

  Gompel, A ^a  

^a Cochin Port Royal ^*  (France)

Author keywords

BREAST CANCER; ENDOMETRIAL CANCER; HORMONE REPLACEMENT THERAPY; MEDROXYPROGESTERONE ACETATE; MPA; PROGESTERONE; PROGESTOGEN

Indexed keywords

CONJUGATED ESTROGEN; DYDROGESTERONE; ESTRADIOL; GLUCOCORTICOID; MEDROXYPROGESTERONE ACETATE; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; PROGESTERONE;

ARTICLE; BREAST CANCER; BREAST CELL; CANCER RISK; DRUG EFFECT; DRUG MECHANISM; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; HORMONE SUBSTITUTION; HUMAN; MULTIPLE CYCLE TREATMENT; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BREAST; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PROGESTERONE; PROGESTINS;

EID: 84858776529     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2012.669584     Document Type: Article

References (27)

1. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientifi c statement. J Clin Endocrinol Metab 2010;95(7 Suppl 1):s1-66
2. Sturdee DW, Pines A; International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14:302-20
3. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17: 242-55
4. Furness S, Roberts H, Marjoribanks J, et al. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2009;(2):CD000402
5. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12 (Pubitemid 38489892)
6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefi ts of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33 (Pubitemid 34761611)
7. Beral V, Bull D, Reeves G; Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-51
8. Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation infl uence risks? J Clin Oncol 2009;27:5138-43
9. Newcomb PA, Trentham-Dietz A. Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States). Cancer Causes Control 2003;14:195-201 (Pubitemid 36539525)
10. J aakkola S, Pukkala E, K Lyytinen, Ylikorkala O. Postmenopausal estradiol-progestagen therapy and risk for uterine cervical cancer. Int J Cancer 2011 Oct 25. Epub ahead of print
11. Allen NE, Tsilidis KK, Key TJ, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol 2010;172:1394-403
12. Bakken K, Fournier A, Lund E, e t al . Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2011;128:144-56
13. Haftenberger M, Schuit AJ, Tormo MJ, e t al . Physical activity of subjects aged 50-64 years involved in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr 2002;5:1163-76
14. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448-54 (Pubitemid 40279968)
15. Sturdee DW, Ulrich LG, Barlow DH, et al. The endometrial response to sequential and continuous combined oestrogen - progestogen replacement therapy. BJOG 2000;107:1392-400
16. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370-5
17. Jondet M, Maroni M, Yaneva H, et al. Comparative endometrial histology in postmenopausal women with sequential hormone replacement therapy of estradiol and, either chlormadinone acetate or micronized progesterone. Maturitas 2002;41:115-21
18. Vogel PM, Georgiade NG, Fetter BF, Vogel FS, McCarty KS Jr. The correlation of histologic changes in the human breast with the menstrual cycle. Am J Pathol 1981;104:23-34 (Pubitemid 11033901)
19. Going JJ, Anderson TJ, Battersby S, MacIntyre CC. Proliferative and secretory activity in human breast during natural and artifi - cial menstrual cycles. Am J Pathol 1988;130:193-204 (Pubitemid 18044847)
20. Longacre TA, Bartow SA. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986;10:382-93 (Pubitemid 16066440)
21. Ramakrishnan R, Khan SA, Badve S. Morphological changes in breast tissue with menstrual cycle. Mod Pathol 2002;15:1348-56 (Pubitemid 35463004)
22. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27 (Pubitemid 36999703)
23. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-11 (Pubitemid 350179584)
24. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009;113:65-73
25. Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defi ned invasive breast cancer. J Clin Oncol 2008;26:1260-8
26. Chang KJ, Lee TT, Linares-Cruz G, Fournier S, de Ligniéres B. Infl uences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 1995;63:785-91
27. Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963-9 (Pubitemid 28193936)